Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004579 | 0.81 | ALOX5 (0.36) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL28030332 | 0.68 | TAS2R46 (0.39) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3672951 | 0.67 | TAS2R46 (0.41) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3672947 | 0.67 | TAS2R46 (0.41) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL7920287 | 0.66 | CHRM2 (0.48) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL20995891 | 0.66 | CHRM2 (0.53) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL7926060 | 0.66 | CHRM2 (0.48) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL7926056 | 0.66 | CHRM2 (0.48) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL789252 | 0.66 | CHRM2 (0.53) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL16321479 | 0.66 | ALOX5 (0.41) | ALOX5TAS2R46 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161306-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161306-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | CHRM2 4830/4885CHRM1 4781/4885MEN1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.